Corient Private Wealth’s Apellis Pharmaceuticals APLS Stock Holding History

Corient Private Wealth’s Portfolio APLS Stock Details APLS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-84,571	Closed	-$3.4M	–	3066
2026 Q1	$3.4M	Buy	+84,571	New	+$1.82M	﹤0.01%	1000

Other funds holding APLS

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Corient Private Wealth's APLS Position: Q2 2026 in Review

Corient Private Wealth sold out of Apellis Pharmaceuticals (APLS) in Q2 2026, closing a stake of 84,571 shares — an estimated $3.4M sold.

Corient Private Wealth first reported a position in APLS in Q1 2026 and held it in 1 quarter. The position peaked at $3.4M in Q1 2026. 1 fund tracked by Wall St. Rank holds APLS as of Q2 2026.

Corient Private Wealth reported no remaining Apellis Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Corient Private Wealth sold 84,571 Apellis Pharmaceuticals shares in Q2 2026, an estimated $3.4M.
Corient Private Wealth first reported a position in Apellis Pharmaceuticals in Q1 2026 and held it in 1 quarter.
Corient Private Wealth's Apellis Pharmaceuticals position peaked at $3.4M in Q1 2026.
1 fund tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q2 2026.

Based on Corient Private Wealth's 13F filing for Q2 2026, filed 12 Aug 2026.